On Jun. 25, 2025, in the midst of a multi-state measles outbreak, a poll by Harvard T.H. Chan…
On Jun. 20, 2025, Vertex Pharmaceuticals announced publication of updated data from the Phase 1/2 portion of the…
On Jun. 17, 2025, Eli Lilly and Verve Therapeutics, a Boston-based clinical-stage company developing genetic medicines for cardiovascular…
On Jun. 16, 2025, Supernus Pharmaceuticals and Sage Therapeutics announced a definitive agreement for Supernus to acquire Sage…
On Jun. 12, 2025, Moderna announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345),…
On Jun. 2, 2025, Sanofi and Blueprint Medicines, a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis…
On May 31, 2025, Moderna announced that the U.S. Food and Drug Administration (FDA) had approved mNEXSPIKE® (mRNA-1283),…
On May 29, 2025, Broad Institute researchers announced they have developed a technology that provides new insight into…
On May 28, 2025, Moderna announced that it has received notice from the U.S. Department of Health and…
On May 23, 2025, a Boston University School of Public Health (BUSPH) led study revealed that there were…
On May 19, 2025, Prime Medicine announced positive initial data from the first patient dosed in its ongoing…
On May 19, 2025, researchers at the Broad Institute Ben Neale and Mark Daly are co-leading the study,…
On Apr. 24, 2025, Thermo Fisher Scientific announced it will will invest an additional $2 billion in the…
On Apr. 9, 2025, a team of neuro scientists scientists published findings from the Machine Intelligence from Cortical…
On Apr. 3, 2025, a collaborative research led by investigators at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center…
On Apr. 2, 2025, Revvity announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure…
On Mar. 10, 2025, Beam Therapeutics announced initial safety and efficacy data from its Phase 1/2 trial of…
On Mar. 3, 2025, Revvity announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support…
On Dec. 11, 2024 the Board of Directors of AquaBounty Technologies announced that the Company was winding down…
On Sept. 17, 2024, Boston Scientific announced the close of its acquisition of Silk Road Medical, a medical…
On Aug. 13, 2024, Eli Lilly announced the opening of the Lilly Seaport Innovation Center (LSC), a research…
On Jul. 2, 2024, Moderna announced a project award of $176 million through the Rapid Response Partnership Vehicle…
On Jun. 20, 2024, the U.S. Food and Drug Administration expanded the approval of Sarepta Therapeutics’ Elevidys (delandistrogene…
On May 31, 2024, Moderna announced that the U.S. Food and Drug Administration (FDA) had approved mRESVIA (mRNA-1345),…
On May 30, 2024, Biogen announced that the European Commission (EC) had granted marketing authorization under exceptional circumstances…
On Apr. 22, 2024, Moderna announced a contract with the Ministry of Health in Brazil (Ministerio da Saude)…
On Mar. 27, 2024, Yield10 Bioscience announced that USDA-APHIS’s Biotechnology Regulatory Services (“BRS”) has determined that Yield10’s Camelina…
On Mar. 21, 2024, Eledon Pharmaceuticals announced that tegoprubart, the company’s investigational anti-CD40L antibody, was used as a…
On Mar. 21, 2024, Harvard Medical School physician-scientists at Massachusetts General Hospital announced they had successfully transplanted a…
On Sept. 26, 2023, the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department…